AirSculpt Technologies (NASDAQ:AIRS) executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S.
Chief Executive Officer Yogi Jashnani described AirSculpt as a “premier body contouring service provider” offering fat removal, fat transfer and skin tightening procedures across 31 corporate centers. He said the company generates about $150 million in revenue, with an approximately 10% EBITDA margin and 60% gross margin.
